BridgeMD
New treatment option for Obesity
Official title A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
ClinicalTrials.gov ID: NCT07215559
What this study is testing
What is Macupatide?
Macupatide is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for obesity.
Also referred to as LY3532226.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Have type 2 diabetes
- Have an HbA1c ≥7.5% to ≤10.5% at screening
- Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening
- Diet and exercise
- Stable dose of metformin
You likely can't join if
- Have any form of diabetes other than type 2 diabetes
- Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening
- Have any of the following cardiovascular conditions within 3 months prior to screening:
- acute myocardial infarction
- cerebrovascular accident (stroke)
- unstable angina, or
See the full eligibility criteria
- Have type 2 diabetes
- Have an HbA1c ≥7.5% to ≤10.5% at screening
- Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening
- Diet and exercise
- Stable dose of metformin
- Sodium-glucose cotransporter-2 (SGLT2) inhibitor
- Have had a stable body weight (\<5% body weight gain and/or loss) for the 3 months prior to screening
- Have a BMI of 27 or greater at screening
- Have any form of diabetes other than type 2 diabetes
- Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening
- Have any of the following cardiovascular conditions within 3 months prior to screening:
- acute myocardial infarction
- cerebrovascular accident (stroke)
- unstable angina, or
- hospitalization due to congestive heart failure
- Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years, exceptions include
- basal or squamous cell skin cancer
- in situ carcinomas of the cervix, or
- in situ prostate cancer
- Have been prescribed any of the following receptor agonists (RA) or their combination for any indication within the last 6 months:
- amylin RA
- dual amylin and calcitonin RA
- glucagon-like peptide-1 receptor (GLP-1) RA
- glucose-dependent insulinotropic peptide (GIP)/GLP-1 RA
- GLP-1/glucagon (GCG) RAs, or
- GIP/GLP-1/GCG RAs
- Have used excluded antihyperglycemic medications within 3 months prior to screening (including, but not limited to, sulfonylureas, dipeptidyl peptidase-4 inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, and...
- Have used insulin for diabetic control within the prior year (short term use in certain situations allowed
The study team makes the final eligibility decision.
Where it's taking place
- Gilbert, Arizona, United States
- Phoenix, Arizona, United States
- Tucson, Arizona, United States
- Sunrise, Florida, United States
- Atlanta, Georgia, United States
- Lawrenceville, Georgia, United States
- Sandy Springs, Georgia, United States
- Stonecrest, Georgia, United States
- Union City, Georgia, United States
- Las Vegas, Nevada, United States
- Trenton, New Jersey, United States
- Dayton, Ohio, United States
- Dallas, Texas, United States
- Houston, Texas, United States
- Richmond, Texas, United States
- Shavano Park, Texas, United States
- Weslaco, Texas, United States
- West Valley City, Utah, United States
- Norfolk, Virginia, United States
- Richmond, Virginia, United States
+ 17 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Gilbert, Arizona, United States; Phoenix, Arizona, United States; Tucson, Arizona, United States; Sunrise, Florida, United States; Atlanta, Georgia, United States; Lawrenceville, Georgia, United States and 31 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.